First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC. Topline data from DENALI Part 2 anticipated by year end 2026 with the potenti ...

In March 2025, Aprea entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center. Aprea has agreed to supply APR-1051 to support preclinical research aimed at exploring its ...

SIR BRADLEY WIGGINS says his children feared for his life as he spiralled into an all-consuming cocaine addiction. The Team GB hero retired from cycling in December 2016 after a glittering career.

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that its Trials in Progress abstract has been selected for ...

VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 ...

"We are excited to continue the clinical development of azenosertib and are proud to take another step forward in addressing the significant unmet need in Cyclin E1+ PROC," said Ingmar Bruns, M.D ...

Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject ...

For adults, a level of vitamin D in the blood of 20 nanograms per milliliter (ng/mL) or above is generally considered adequate. Levels below 20 ng/mL are generally too low for adequate bone health ...

Medicare Part D prescription drug plans cover many take-home medications. Stand-alone Part D plans work with Original Medicare, but most Medicare Advantage plans also include Part D coverage.

This regulatory link appears to be particularly important in pathological conditions such as cancer, where cyclin D levels are elevated. Strengths: The authors support their findings with several ...

Presentation Details Title: Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated ... Marie Evangelista, and Pablo D. Garcia, Circle Pharma Inc., South San Francisco, CA, University of ...